resiquimod hydrogel-based sustained-release formulation

{
  "id": "MLC-T-ONC-016497",
  "term": "resiquimod hydrogel-based sustained-release formulation",
  "field": "Oncology and biomedicine",
  "definition": "A hydrogel carrier-based, sustained intra-tumoral release formulation of resiquimod, a Toll-like receptor (TLR) 7/8 agonist and an imidazoquinolinamine, with potential immunostimulating and antineoplastic activities. Upon intra-tumoral administration, resiquimod binds to TLR7 and 8, which are found mainly on dendritic cells (DCs), macrophages, and B lymphocytes, and activates the TLR signaling pathway, which results in the induction of the nuclear translocation of transcription activator nuclear factor kappa-B (NF-kB) and activation of other transcription factors. Subsequently, NF-kB-dependent gene expression is induced and cytokine production increases, especially interferon-alpha (INF-a), which results in the enhancement of T-helper 1 (Th1) immune responses. Activation of DCs also results in the activation of cytotoxic T-lymphocyte (CTL) and B-lymphocyte immune responses. This may cause tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the immune system.",
  "synonyms": [
    "localized release TLR7/8 agonist",
    "TransCon TLR7/8 agonist",
    "intratumoral release TLR7/8 agonist"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/resiquimod-hydrogel-based-sustained-release-formulation/"
}